Neurotech International Ltd. has released a press release.
NTI Doses First Patient in Phase 3 Beyond Harmony ASD Study
Earlier from Neurotech International
- Receipt of Binding Commitments for $4.5m Placement
- Neurotech secures $3.15 million R&D tax incentive loan
- US FDA clears IND for NTI164
- NTI secures Notices of Allowance for US patent applications